Telix brain cancer data lifts FDA approval hopes
MELBOURNE: Telix Pharmaceuticals shares are up 2.2 per cent at $16.53 after hitting ...
To read the full story...SUBSCRIBE NOWExisting Subscribers Login Below:
Log In
